Overall survival in metastatic non-small cell lung cancer is improved by immunotherapy but individual responses widely vary, and predictive biomarkers are urgently needed. Here authors show that multimodal markers, based on clinical, pathological, radiological, and transcriptomic data are more reliable at patient risk stratification than unimodal markers, considering one type of input data only.
- Nicolas Captier
- Marvin Lerousseau
- Emmanuel Barillot
